The company’s Antisense molecular diagnostic platform is being developed for use at Point of Care (POC) to test on-site for a wide range of viral and other diseases.
The Company’s first product is an Antisense molecular Point of Care (POC) diagnostic test kit that accurately, quickly and affordably detects Covid-19 in less than 5 minutes.
Deployed at the point of entry of high traffic venues such as airports, shopping malls, office buildings, sporting venues, manufacturing plants, hospitals, pharmacies, nursing and long-term care homes the Antisense POC molecular diagnostic test kit will contribute to safe reopening of the economy.
Insert patient sample swab into cartridge, close cap of cartridge, insert cartridge into instrument reader to individually run diagnostic test. Once test cycle completes the result will automatically be sent to electronic devices - smart phones, Ipads or computers.
We have established a world class executive leadership team, Board of Directors and Board of Advisors, with experience in healthcare, life sciences, medical devices, diagnostics, biotechnology, nanomedicine, drug delivery, and pharmaceuticals. Our financial advisors have decades of global experience in investment banking in the private and public sector.LEARN MORE
RNA Disease Diagnostics, Inc. (RNADD) announced today the appointment of Richard G. Ganz to its Board of Directors. Mr. Ganz brings more than forty years of executive experience to RNADD, having worked with businesses ranging from venture-backed startups to major international healthcare companies.Read More
RNA Disease Diagnostics, Inc. (RNADD) announced today that the U.S. Food and Drug Administration (FDA) has registered the laboratory of Dipanjan Pan, MSc, PhD at the University of Maryland School of Medicine (UMSOM), as an approved laboratory development site for RNADD's Antisense COVID-19 molecular diagnostic test.Read More